Administration of 177Lu–FAP‐2286 was well tolerated, with no adverse symptoms or clinically detectable pharmacologic effects reported in any of the patients. Significant uptake and prolonged tumor retention of 177Lu–FAP‐2286 resulted in high absorbed tumor doses. This evidence concerns the gene FAP and neoplasm.